Searchable abstracts of presentations at key conferences in endocrinology

ea0070aep758 | Pituitary and Neuroendocrinology | ECE2020

Silent corticotroph adenoma: Experience with six cases

Serra Soler Guillermo , Antich Barceló Carlos , Bodoque Cubas Javier , García Fernández Honorato , Mas Bonet Antonio , Antón Valentí Ester , Mena Ribas Elena , Tofé Povedano Santiago , Argüelles Jiménez Iñaki , Pereg Macazaga Vicente

Introduction: Silent corticotroph adenomas (SCA) represent a subtype of pituitary adenomas whose prevalence is 3% of pituitary adenomas. They are characterized by having a positive immunohistochemistry to corticotropin (ACTH) without clinical or biochemical data of hypercortisolism. The diagnosis is a challenge since they are considered as ANF, and it is with the pathology report after surgery when they are classified as SCA. They have more aggressive behavior and recur more t...

ea0098b26 | Basic Science | NANETS2023

Cancer testis antigen and interleukin expression correlates with survival in small bowel neuroendocrine tumors

David Seo MD Y. , Witt MD, MAS Russell G. , Lazcano MD Rossana , MD Samuel Cass , Hudgens Courtney , Wani Khalida , Chelvanambi PhD Manoj , Johnson MS Sarah , Hernandez MD Sharia D. , Halperin MD Daniel M. , Lazar MD, PhD Alexander J. , Wargo MD, MMSc Jennifer A. , Estrella MD Jeannelyn S. , Maxwell MD, MBA Jessica E.

Background: Patients with small bowel neuroendocrine tumors (SBNETs) frequently present with metastatic disease, and unfortunately, the range and efficacy of available therapies is limited. Immunotherapeutic checkpoint inhibitors have demonstrated benefit in other malignancies and may also play a role in SBNETs, although relatively little is known about the immune infiltrate in these tumors. Toward a goal of developing novel immunomodulatory strategies, we sought to evaluate t...